Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by BioMarin Pharmaceutical
Sponsor:
Collaborators:
National Breast Cancer Coalition (NBCC)
Translational Research in Oncology
US Oncology Research
Myriad Genetics, Inc.
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01945775
First received: September 11, 2013
Last updated: November 10, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)